Produced By Deanna Utroske, 2
This month, multinational bioprinting technologies company Cellink announced having reached a deal to acquire Cytena for €30.25 million. The Freiburg, Germany – based venture specialises in single-cell printing technology. And the deal will expand Cellink’s capabilities in both pharma and cosmetics.
Cellink got its start in 2016 and is headquartered in Boston, Massachusetts, (in the US) where a lot of biotech businesses are located. The company makes and commercializes bioprinting technologies for use in academic research and industry. Bioprinting is essentially 3-dimentional printing technology that incorporates live cells and is used to create tissue and other components.
Explore Trends and Innovations at NYSCC To register, click here 📅 on Tuesday May…
Roger Guillemin identified the molecules in the brain that control the production of hormones in…
In 2007, Sinclair wrote the article “Healthy Hair: What is it?” in which he stated,…